STL Volume 22 Number 6
3 POSTS 0 COMMENTSPurchase PDF for $2.79
Dupilumab for Moderate-to-Severe Atopic Dermatitis
Despite a rising prevalence, effective and safe therapeutics for patients with moderate-to-severe AD are limited due to toxicity and side effects. Dupilumab, an interleukin (IL)-4 and IL-13 antagonist that limits type 2 T helper (Th2) driven inflammatory activity, is a promising therapeutic option.
Real-World Efficacy of Azelaic Acid 15% Gel for the Reduction of Inflammatory Lesions of...
Use of azelaic acid was associated with a significant reduction in inflammatory lesions, which persisted beyond the active treatment phase. Overall, azelaic acid 15% gel is an appropriate initial topical therapy for the treatment of moderate facial rosacea.
Update on Drugs and Drug News: November-December 2017
November-December 2017 Update on drugs includes Adalimumab-adbm for SC injection Cyltezo™, Adalimumab biosimilar Imraldi®, Cemiplimab REGN2810, Oral migalastat Galafold™, and Secnidazole oral granules Solosec™